1 Stock Make It On Today's Healthcare & Biotech Stock Watchlist
Powered by HealthTechMovers.com
We added 1 stock to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Incyte, INCY
Summary: Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.
- Last Price: 66.63
- Price Change: 1.67, 2.57%
- Yearly Gain: -21.04%
- Market Cap: 14.72B
- P/E Ratio: 28
Here are 3rd party ratings for INCY:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 36% (163 out of 254)
What is the sentiment on the street regarding Incyte ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in INCY or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on INCY before you decide to make any investment.
Click here for chart >>
Thanks for reading!